Vipshop Holdings Ltd – ADR (VIPS) Reaches $8.85 1 Year Low; Harvard Bioscience (HBIO) Shorts Lowered By 1.49%

August 28, 2017 - By Clifton Ray

Harvard Bioscience Incorporated (NASDAQ:HBIO) had a decrease of 1.49% in short interest. HBIO’s SI was 520,700 shares in August as released by FINRA. Its down 1.49% from 528,600 shares previously. With 57,100 avg volume, 9 days are for Harvard Bioscience Incorporated (NASDAQ:HBIO)’s short sellers to cover HBIO’s short positions. The SI to Harvard Bioscience Incorporated’s float is 1.77%. About 2,127 shares traded. Harvard Bioscience, Inc. (NASDAQ:HBIO) has declined 25.93% since August 28, 2016 and is downtrending. It has underperformed by 42.63% the S&P500.

The stock of Vipshop Holdings Ltd – ADR (NYSE:VIPS) hit a new 52-week low and has $8.32 target or 6.00% below today’s $8.85 share price. The 9 months bearish chart indicates high risk for the $5.22 billion company. The 1-year low was reported on Aug, 28 by Barchart.com. If the $8.32 price target is reached, the company will be worth $313.20M less. About 1.68M shares traded. Vipshop Holdings Ltd – ADR (NYSE:VIPS) has risen 27.19% since August 28, 2016 and is uptrending. It has outperformed by 10.49% the S&P500.

Among 15 analysts covering Vipshop Holdings Limited (NYSE:VIPS), 8 have Buy rating, 3 Sell and 4 Hold. Therefore 53% are positive. Vipshop Holdings Limited had 27 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was initiated by Bernstein on Wednesday, January 11 with “Underperform”. The stock of Vipshop Holdings Ltd – ADR (NYSE:VIPS) has “Neutral” rating given on Monday, November 16 by Bank of America. The firm has “Buy” rating by Brean Capital given on Thursday, November 19. The stock of Vipshop Holdings Ltd – ADR (NYSE:VIPS) has “Neutral” rating given on Wednesday, May 18 by JP Morgan. The stock of Vipshop Holdings Ltd – ADR (NYSE:VIPS) has “Buy” rating given on Thursday, January 7 by Credit Agricole. The company was downgraded on Monday, November 16 by Credit Agricole. HSBC downgraded the stock to “Reduce” rating in Friday, August 18 report. The stock of Vipshop Holdings Ltd – ADR (NYSE:VIPS) earned “Buy” rating by Jefferies on Monday, August 14. The company was downgraded on Wednesday, August 17 by Deutsche Bank. Deutsche Bank downgraded the stock to “Hold” rating in Friday, June 30 report.

Vipshop Holdings Limited is a holding company. The company has market cap of $5.22 billion. The Firm is an online discount retailer for brands in China. It has a 18.48 P/E ratio. The Firm offers branded products to clients in China through flash sales mainly on its vip.com Website.

Among 2 analysts covering Harvard Bioscience Inc (NASDAQ:HBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Harvard Bioscience Inc had 2 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Harvard Bioscience, Inc. (NASDAQ:HBIO) earned “Buy” rating by Benchmark on Tuesday, July 28. The firm earned “Buy” rating on Thursday, November 17 by Singular Research.

Investors sentiment increased to 1.09 in Q4 2016. Its up 0.09, from 1 in 2016Q3. It is positive, as 6 investors sold Harvard Bioscience, Inc. shares while 13 reduced holdings. 8 funds opened positions while 25 raised stakes. 20.98 million shares or 5.59% less from 22.23 million shares in 2016Q3 were reported. Eagle Advsr Limited Liability Corp accumulated 156,276 shares. Acadian Asset Mgmt Limited Company has invested 0.01% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Bard Associates invested in 359,525 shares. Price T Rowe Md holds 28,200 shares. Manufacturers Life Insurance Communication The reported 1,760 shares stake. 19,300 were accumulated by Schwab Charles Inv Mngmt. D E Shaw & Communications holds 0% or 77,183 shares in its portfolio. California Employees Retirement has 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO). Heartland Advsrs Inc owns 0.34% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 2.00M shares. Glacier Peak Capital Ltd Co owns 1.16 million shares or 2.03% of their US portfolio. Royal Retail Bank Of Canada accumulated 0% or 61 shares. Bridgeway Capital Inc holds 0.01% in Harvard Bioscience, Inc. (NASDAQ:HBIO) or 369,017 shares. Granahan Invest Mgmt Ma, a Massachusetts-based fund reported 1.54 million shares. Millennium Ltd has 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 28,967 shares. 209,176 are held by Clarivest Asset Ltd.

Since May 23, 2017, it had 4 insider buys, and 0 insider sales for $74,561 activity. 12,238 shares valued at $28,765 were bought by LEWIS EARL R on Thursday, May 25. 1,000 shares valued at $2,330 were bought by Gagnon Robert E. on Thursday, May 25. Shares for $19,666 were bought by Green James W on Thursday, June 8.

Harvard Bioscience, Inc. is a developer, maker and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The company has market cap of $103.22 million. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. It currently has negative earnings. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology , Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA).